GlassScriptPhysician profile
Maham Ashraf
NPI 1912211442
$537.97
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $56.41 · 2021: $104 · 2022: $42.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $339.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $102.87 | 2019-2020 | |
| Mylan Specialty L.P. | $49.25 | 2019 | |
| Boston Scientific Corporation | $29.10 | 2020 | |
| Vyera Pharmaceuticals, LLC | $17.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maham Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.